title: Target haematocrit during erythropoietin therapy.
authors.forename: A R
authors.initials: AR
authors.lastname: Nissenson
authors.forename: A
authors.initials: A
authors.lastname: Besarab
authors.forename: W K
authors.initials: WK
authors.lastname: Bolton
authors.forename: D A
authors.initials: DA
authors.lastname: Goodkin
authors.forename: S J
authors.initials: SJ
authors.lastname: Schwab
mesh_terms: D002319:Cardiovascular System / Q000503:physiopathology; D002408:Catheters, Indwelling / Q000009:adverse effects; D004921:Erythropoietin / Q000627:therapeutic use*; D006400:Hematocrit; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D010807:Physical Endurance; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin